The lumbosacral radicular pain market size has grown strongly in recent years. It will grow from $0.91 billion in 2024 to $0.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be credited to the rising prevalence of lower back disorders, a growing elderly population experiencing spinal problems, an increase in sedentary lifestyles and poor posture, heightened demand for pain management treatments, and greater awareness regarding early diagnosis and intervention.
The lumbosacral radicular pain market size is expected to see strong growth in the next few years. It will grow to $1.21 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The projected growth in the forecast period can be attributed to advancements in pain management technologies, a growing emphasis on non-opioid treatment alternatives, increased investment in spinal research and development, rising demand for outpatient and minimally invasive procedures, and improved access to healthcare in emerging markets. Key trends expected during this period include progress in minimally invasive surgical techniques, the development of targeted anti-inflammatory medications, innovations in wearable pain management devices, advanced imaging methods for identifying nerve roots, and the creation of personalized treatment plans based on patient-specific data.
The rising prevalence of degenerative spinal conditions is anticipated to drive the growth of the lumbosacral radicular pain market in the coming years. Degenerative spinal conditions encompass a range of disorders resulting from the progressive deterioration of the spine over time. This increase is primarily driven by aging populations and lifestyle factors that contribute to spinal degeneration and nerve compression, leading to greater demand for effective diagnosis and treatment. Lumbosacral radicular pain serves as an indicator of underlying degenerative spinal issues by highlighting nerve root irritation or compression, thereby aiding clinical assessment and treatment planning. For example, in May 2023, the University of Sydney, an Australia-based public university, projected that over 800 million people globally will experience back pain by 2050. As a result, the growing incidence of degenerative spinal conditions is a key factor fueling the expansion of the lumbosacral radicular pain market.
Leading companies in the lumbosacral radicular pain market are prioritizing the development of advanced minimally invasive neuromodulation therapies, including compact and rechargeable spinal cord stimulation (SCS) systems, to improve pain relief and enhance patient comfort. These miniaturized SCS devices are implantable and deliver electrical impulses to the spinal cord to disrupt pain signals, providing extended battery life and less invasive treatment options. For example, in December 2022, Abbott Laboratories, a U.S.-based healthcare company, introduced the Eterna spinal cord stimulation system designed to deliver advanced BurstDR therapy for chronic pain management. This system features state-of-the-art rechargeable battery technology that significantly lengthens the time between recharges, reducing inconvenience for patients. It also includes proprietary stimulation patterns, such as BurstDR, that replicate natural nerve activity for more effective and sustained pain relief. Additionally, the device is MRI-compatible, allowing patients to safely undergo full-body scans without device removal. Its design is also upgrade-friendly, enabling patients to access future technological improvements without requiring further surgeries.
In October 2024, Stryker Corporation, a U.S.-based medical technology company, acquired Vertos Medical Inc. for an undisclosed sum. This acquisition is intended to bolster Stryker’s portfolio of minimally invasive spine treatments by incorporating Vertos Medical’s innovative technologies, improving patient outcomes, and reinforcing its position as a leader in the spinal health market. Vertos Medical Inc. is a U.S.-based company focused on minimally invasive treatments for lumbar spinal stenosis (LSS).
Major players in the lumbosacral radicular pain market are Pfizer Inc., Johnson & Johnson Services Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Eli Lilly and Company, Boston Scientific Corporation, Vertex Pharmaceuticals, Biotronik, Nevro Corp., Sorrento Therapeutics, Scilex Holding Company, ProMed Pharma, SPR Therapeutics, Saluda Medical Pty Ltd., Eliem Therapeutics, Cephalon Inc., Semnur Pharmaceuticals Inc., Nalu Medical Inc., Sollis Therapeutics Inc.
North America was the largest region in the lumbosacral radicular pain market in 2024. The regions covered in lumbosacral radicular pain report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the lumbosacral radicular pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Lumbosacral radicular pain is a type of pain that begins in the lower spine (lumbar and sacral areas) and travels along the course of a spinal nerve into the leg. It is most often caused by compression or irritation of the nerve root, typically resulting from conditions like a herniated disc or spinal stenosis.
The primary categories of treatment for lumbosacral radicular pain include pharmacological therapies, non-pharmacological approaches, and interventional procedures. Pharmacological therapies involve the use of drugs or medications to diagnose, manage, or prevent health conditions. These medications can be administered through various methods, including oral, topical, injectable, and implantable routes. The distribution of these drugs occurs through different channels such as hospital pharmacies, retail pharmacies, and online pharmacies, serving a range of end-users including hospitals, specialty clinics, rehabilitation centers, and homecare environments.
The lumbosacral radicular pain market research report is one of a series of new reports that provides lumbosacral radicular pain market statistics, including the lumbosacral radicular pain industry global market size, regional shares, competitors with the lumbosacral radicular pain market share, detailed lumbosacral radicular pain market segments, market trends, and opportunities, and any further data you may need to thrive in the lumbosacral radicular pain industry. This lumbosacral radicular pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The lumbosacral radicular pain market includes revenues earned by entities by providing services such as non-surgical treatment services, interventional pain management services, and rehabilitation and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The lumbosacral radicular pain market size is expected to see strong growth in the next few years. It will grow to $1.21 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The projected growth in the forecast period can be attributed to advancements in pain management technologies, a growing emphasis on non-opioid treatment alternatives, increased investment in spinal research and development, rising demand for outpatient and minimally invasive procedures, and improved access to healthcare in emerging markets. Key trends expected during this period include progress in minimally invasive surgical techniques, the development of targeted anti-inflammatory medications, innovations in wearable pain management devices, advanced imaging methods for identifying nerve roots, and the creation of personalized treatment plans based on patient-specific data.
The rising prevalence of degenerative spinal conditions is anticipated to drive the growth of the lumbosacral radicular pain market in the coming years. Degenerative spinal conditions encompass a range of disorders resulting from the progressive deterioration of the spine over time. This increase is primarily driven by aging populations and lifestyle factors that contribute to spinal degeneration and nerve compression, leading to greater demand for effective diagnosis and treatment. Lumbosacral radicular pain serves as an indicator of underlying degenerative spinal issues by highlighting nerve root irritation or compression, thereby aiding clinical assessment and treatment planning. For example, in May 2023, the University of Sydney, an Australia-based public university, projected that over 800 million people globally will experience back pain by 2050. As a result, the growing incidence of degenerative spinal conditions is a key factor fueling the expansion of the lumbosacral radicular pain market.
Leading companies in the lumbosacral radicular pain market are prioritizing the development of advanced minimally invasive neuromodulation therapies, including compact and rechargeable spinal cord stimulation (SCS) systems, to improve pain relief and enhance patient comfort. These miniaturized SCS devices are implantable and deliver electrical impulses to the spinal cord to disrupt pain signals, providing extended battery life and less invasive treatment options. For example, in December 2022, Abbott Laboratories, a U.S.-based healthcare company, introduced the Eterna spinal cord stimulation system designed to deliver advanced BurstDR therapy for chronic pain management. This system features state-of-the-art rechargeable battery technology that significantly lengthens the time between recharges, reducing inconvenience for patients. It also includes proprietary stimulation patterns, such as BurstDR, that replicate natural nerve activity for more effective and sustained pain relief. Additionally, the device is MRI-compatible, allowing patients to safely undergo full-body scans without device removal. Its design is also upgrade-friendly, enabling patients to access future technological improvements without requiring further surgeries.
In October 2024, Stryker Corporation, a U.S.-based medical technology company, acquired Vertos Medical Inc. for an undisclosed sum. This acquisition is intended to bolster Stryker’s portfolio of minimally invasive spine treatments by incorporating Vertos Medical’s innovative technologies, improving patient outcomes, and reinforcing its position as a leader in the spinal health market. Vertos Medical Inc. is a U.S.-based company focused on minimally invasive treatments for lumbar spinal stenosis (LSS).
Major players in the lumbosacral radicular pain market are Pfizer Inc., Johnson & Johnson Services Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Eli Lilly and Company, Boston Scientific Corporation, Vertex Pharmaceuticals, Biotronik, Nevro Corp., Sorrento Therapeutics, Scilex Holding Company, ProMed Pharma, SPR Therapeutics, Saluda Medical Pty Ltd., Eliem Therapeutics, Cephalon Inc., Semnur Pharmaceuticals Inc., Nalu Medical Inc., Sollis Therapeutics Inc.
North America was the largest region in the lumbosacral radicular pain market in 2024. The regions covered in lumbosacral radicular pain report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the lumbosacral radicular pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Lumbosacral radicular pain is a type of pain that begins in the lower spine (lumbar and sacral areas) and travels along the course of a spinal nerve into the leg. It is most often caused by compression or irritation of the nerve root, typically resulting from conditions like a herniated disc or spinal stenosis.
The primary categories of treatment for lumbosacral radicular pain include pharmacological therapies, non-pharmacological approaches, and interventional procedures. Pharmacological therapies involve the use of drugs or medications to diagnose, manage, or prevent health conditions. These medications can be administered through various methods, including oral, topical, injectable, and implantable routes. The distribution of these drugs occurs through different channels such as hospital pharmacies, retail pharmacies, and online pharmacies, serving a range of end-users including hospitals, specialty clinics, rehabilitation centers, and homecare environments.
The lumbosacral radicular pain market research report is one of a series of new reports that provides lumbosacral radicular pain market statistics, including the lumbosacral radicular pain industry global market size, regional shares, competitors with the lumbosacral radicular pain market share, detailed lumbosacral radicular pain market segments, market trends, and opportunities, and any further data you may need to thrive in the lumbosacral radicular pain industry. This lumbosacral radicular pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The lumbosacral radicular pain market includes revenues earned by entities by providing services such as non-surgical treatment services, interventional pain management services, and rehabilitation and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Lumbosacral Radicular Pain Market Characteristics3. Lumbosacral Radicular Pain Market Trends And Strategies4. Lumbosacral Radicular Pain Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Lumbosacral Radicular Pain Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Lumbosacral Radicular Pain Market34. Recent Developments In The Lumbosacral Radicular Pain Market
5. Global Lumbosacral Radicular Pain Growth Analysis And Strategic Analysis Framework
6. Lumbosacral Radicular Pain Market Segmentation
7. Lumbosacral Radicular Pain Market Regional And Country Analysis
8. Asia-Pacific Lumbosacral Radicular Pain Market
9. China Lumbosacral Radicular Pain Market
10. India Lumbosacral Radicular Pain Market
11. Japan Lumbosacral Radicular Pain Market
12. Australia Lumbosacral Radicular Pain Market
13. Indonesia Lumbosacral Radicular Pain Market
14. South Korea Lumbosacral Radicular Pain Market
15. Western Europe Lumbosacral Radicular Pain Market
16. UK Lumbosacral Radicular Pain Market
17. Germany Lumbosacral Radicular Pain Market
18. France Lumbosacral Radicular Pain Market
19. Italy Lumbosacral Radicular Pain Market
20. Spain Lumbosacral Radicular Pain Market
21. Eastern Europe Lumbosacral Radicular Pain Market
22. Russia Lumbosacral Radicular Pain Market
23. North America Lumbosacral Radicular Pain Market
24. USA Lumbosacral Radicular Pain Market
25. Canada Lumbosacral Radicular Pain Market
26. South America Lumbosacral Radicular Pain Market
27. Brazil Lumbosacral Radicular Pain Market
28. Middle East Lumbosacral Radicular Pain Market
29. Africa Lumbosacral Radicular Pain Market
30. Lumbosacral Radicular Pain Market Competitive Landscape And Company Profiles
31. Lumbosacral Radicular Pain Market Other Major And Innovative Companies
35. Lumbosacral Radicular Pain Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Lumbosacral Radicular Pain Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on lumbosacral radicular pain market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for lumbosacral radicular pain ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lumbosacral radicular pain market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment Type: Pharmacological Treatment; Non-Pharmacological Treatment; Interventional Procedures2) By Route Of Administration: Oral; Topical; Injectable; Implantable
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Hospitals; Specialty Clinics; Rehabilitation Centers; Homecare Settings
Subsegments:
1) By Pharmacological Treatment: Nonsteroidal Anti-Inflammatory Drugs; Opioids; Anticonvulsants; Antidepressants; Muscle Relaxants; Corticosteroids2) By Non-Pharmacological Treatment: Physical Therapy; Exercise And Rehabilitation Programs; Chiropractic Care; Acupuncture; Cognitive Behavioral Therapy; Heat And Cold Therapy
3) By Interventional Procedures: Epidural Steroid Injections; Radiofrequency Ablation; Nerve Root Blocks; Spinal Cord Stimulation; Minimally Invasive Decompression; Intrathecal Drug Delivery Systems
Key Companies Profiled: Pfizer Inc.; Johnson & Johnson Services Inc.; Abbott Laboratories; Novartis AG; Medtronic plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Abbott Laboratories
- Novartis AG
- Medtronic plc
- Eli Lilly and Company
- Boston Scientific Corporation
- Vertex Pharmaceuticals
- Biotronik
- Nevro Corp.
- Sorrento Therapeutics
- Scilex Holding Company
- ProMed Pharma
- SPR Therapeutics
- Saluda Medical Pty Ltd.
- Eliem Therapeutics
- Cephalon Inc.
- Semnur Pharmaceuticals Inc.
- Nalu Medical Inc.
- Sollis Therapeutics Inc.